the results that biocon demonstrated are very encouraging that, as you highlighted. they treated 30 patients. 20 patients were given the drug, ten patients were given care -- >> laura: bruce, real quick. some also had pre-existing conditions that increased the risk of death from covid, correct? so that's really keep it real quick bread >> . >> elderly patients, patients who have significantly higher risk. and the incoming baseline characteristics for these patients did include a lot of those high risk factors the background in these patients who were presenting with moderate to severely ill syndromes and key respiratory syndromes in covid-19 patients to have a background mortality late don't migrate that is the 40-50%. it went okay, so this is key. the next step -- we are going to track the progress of your work trying to get this into the fda for trials here in the united states. but i -- i'm impressed cautiously thus far with what they have been able to do. biocon and i am so glad you have this ownership with them. we wish you all the best. we know is a long road t